Latest news with #Alzheimer's
NDTV
2 hours ago
- Entertainment
- NDTV
Ahaan Panday Thanks Fans "For All The Love" As Saiyaara Completes A Week Since Release
New Delhi: Ahaan Panday as Krish Kapoor in Saiyaara has scripted history as a newcomer. The Mohit Suri film starring Aneet Padda in the lead has had an unprecedented opening at the box office, and continues to rake in numbers every day. The film completed one week of its release today. Ahaan Panday took to Instagram to share a series of BTS pictures from Saiyaara. He captioned it, "One week of Saiyaara, thank you for the love." View this post on Instagram A post shared by Ahaan Panday (@ahaanpandayy) Ahaan Panday's Rapidly Growing Instagram Followers Saiyaara's roaring success streak has taken Ahaan Panday to overnight fame. In another milestone achievement, the 27-year-old now boasts more than 1 million followers on Instagram. The spike in numbers comes after the movie's release, before which he had around 460K-480K followers. At present, Ahaan Panday's Instagram follower list has skyrocketed to an impressive 1.5 million. About Saiyaara Saiyaara, produced by Yash Raj Film, is an intense love story between a young couple - struggling musician Krish Kapoor (Ahaan Panday) and an aspiring writer Vaani Batra (Aneet Padda), diagnosed with early-onset Alzheimer's disease. Together they embark on a journey of love, loss and heartbreak. In A Nutshell Ahaan Panday took to Instagram to thank his fans for all the love they have been showering on him ever since Saiyaara. He shared a series of BTS pictures from his debut film in his onscreen avatar as Krish Kapoor.
Euractiv
3 hours ago
- Health
- Euractiv
EU medicines agency reverses course on Eli Lilly's Alzheimer drug
The European Medicines Agency (EMA) has reversed its stance on Eli Lilly's Alzheimer's drug Kisunla, recommending its approval for limited use just months after initially rejecting it due to safety concerns. In March, the EMA's drug safety committee said the risks of the drug outweighed its benefits, citing rare but potentially fatal side effects such as brain swelling and bleeding. However, the agency now says the drug can be authorised for patients who either do not carry the ApoE4 gene or who carry only one copy of it, as this gene makes patients more susceptible to brain bleeding. Treatments for the neurological disease remain costly and carry significant risks, offering only modest clinical benefit. But while Kisunla has already been approved in the US, UK, Japan, and China, Europe's slower response has raised concern among patient groups. Alzheimer Europe welcomed the move, saying that they appreciated 'the careful approach that the EMA has taken to identify patients likely to benefit from treatment and to exclude those at greatest risk of harmful side-effects, such as people with two copies of the ApoE4 gene.' "As with all anti-amyloid therapies, concerns around safety remain, and ongoing vigilance will be essential to ensure a favourable benefit-risk balance in real-world use,' Jean Georges, the Executive Director of Alzheimer Europe said in a press release. This is not the first time the EMA has changed its position on Alzheimer's treatments. In 2024, it initially rejected Leqembi, developed by US firm Biogen and Japan's Eisai, before later approving it for a more narrow patient group. The EMA's recommendation is pending a final decision from the European Commission. (de)
Newsweek
5 hours ago
- Health
- Newsweek
Tiny 'Flowers' Offer New Hope Against Alzheimer's and Parkinson's
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Tiny, metallic, flower-shaped nanoparticles may offer fresh hope for patients with neurodegenerative diseases like Alzheimer's and Parkinson's. This is the conclusion of researchers from Texas A&M University, who found that the so-called nanoflowers can protect and heal brain cells. The do this by promoting the health and turnover of mitochondria—the oft-dubbed "powerhouses of the cell" which are responsible for turning food into energy. While this process is essential for life, the mitochondria also produce waste in the process—including so-called "reactive oxygen species"—which can damage cells. The finding could pave the way for new treatments for neurological diseases that address the underlying root causes—in this case mitochondrial health and oxidative stress—instead of just managing symptoms. "We expect that our drug can reverse neuronal damage and consequently reverse neurodegeneration," study lead and biochemist professor Dmitry Kurouski told Newsweek. Alzheimer's is the most common neurodegenerative disease with Parkinson's coming in second—and promising new treatments are much sought after. In fact, more than seven million Americans are living with Alzheimer's, a figure projected to rise to nearly 13 million by 2050, according to the Alzheimer's Association. Meanwhile, around 1.1 million people in the U.S. are living with Parkinson's, expected to rise to 1.2 million by 2030, according to Parkinson's Foundation. Alongside potentially helping combat Alzheimer's and Parkinson's, Kurouski said, "it is important to mention that similar reversing effects could be expected in other pathologies including acute brain and spinal cord injuries." Doctor and older patient smile while looking at phone results, with inserted image of nanoflowers overlayed in corner. Doctor and older patient smile while looking at phone results, with inserted image of nanoflowers overlayed in corner. Lacheev / iStock / Getty Images Plus / Journal of Biological Chemistry In their study, Kurouski and colleagues explored—in a petri dish in the lab—how nanoflowers affect both the brain's nerve cells, or 'neurons', and the star-shaped 'astrocytes' that support them. Within 24 hours of treatment, the team saw a "dramatic" drop in the levels of ROS, accompanied by signs of improved mitochondrial function. "Even in healthy cells, some oxidative stress is expected. But the nanoflowers seem to fine-tune the performance of mitochondria, ultimately bringing the levels of their toxic byproducts down to almost nothing," Kurouski explained. Having assessed the effects on individual cells, the researchers next tested the impact of the nanoflowers on whole creatures—specifically a species of worm, C. elegans, which is commonly used as a model organism in neurological research. The team found that, on average, worms treated with one specific flavor of nanoflower survived for days longer than their untreated counterparts (which typically live for around 18 days) and were less likely to die during the early stages of their lives. "These nanoflowers look beautiful under a microscope, but what they do inside the cell is even more impressive," Kurouski said in a statement. "By improving the health of brain cells, they help address one of the key drivers of neurodegenerative diseases that have long resisted therapeutic breakthroughs." With more research needed before clinical trials could be conducted on humans, Kurouski says he plans to undertake further studies in more complex animal models. The team are also exploring practical concerns towards clinical applications. "We are currently working on finding the best way to administrate the drug. We anticipate that internasal spray will be the best solution," Kurouski said. The biochemist stressed that he is keen to make sure the nanoflowers are safe, effective and have clear mechanism of action—but, he concluded, he thinks they could be a "new class of therapeutics" with "incredible potential." Do you have a health story to share with Newsweek? Do you have a question about the study? Let us know via health@ Reference Mitchell, C. L., Matveyenka, M., & Kurouski, D. (2025). Neuroprotective properties of transition metal dichalcogenide nanoflowers alleviate acute and chronic neurological conditions linked to mitochondrial dysfunction. Journal of Biological Chemistry, 301(5).
Time of India
6 hours ago
- Entertainment
- Time of India
'Twinkle Khanna could not carry Mela on her shoulders, it needed Karisma Kapoor,' says Suneel Darshan, reveals Aamir Khan added brother's character in the film
'Mela' which starred , and was not only a box office dud but the film is still made fun of, over the years. Infact, Twinkle herself has joked about the fact that she wants to forget the film. In a recent interview, producer who had also written the script of the film has reflected on what went wrong with the film. 'Mela' also led to Suneel's fallout with his brother . Tired of too many ads? go ad free now He said durin a chat with Vickey Lalwani, "The original story of Mela was written be me. The title was mine. They went ahead and made the movie. They cast Twinkle Khanna in the movie, which was a miscasting. The movie needed a , and unfortunately, she was not cast in the film. You needed a girl who could carry the movie on her shoulders. I felt that she was not right for the movie.' Suneel explained that the original story he wrote was altered, and Aamir had to take permission from him. The biggest modification, according to Suneel, was the addition of the character played by Faisal, who wasn't in the original version of the script written by him.. 'He added the brother's character. Otherwise, everything else was mine.' Later on, Aamir realised he needed the proper permissions and reached out to Suneel. 'He got through to me, and I had no choice but to agree.' Meanwhile, Twinkle who is known a wellknown writer and quite good at it, had admitted that she was never made for acting. She had said at an event, 'I have not given any hit film. Whatever films I have done should be banned and (no one should watch) it. Most of the time, I pretend I have Alzheimer's and I don't remember my film career and it makes me happy that ways.' Talking about his fallout with brother Dharmesh, Suneel said, "Some things don't work out. People have their own thinking, and approach, and attitude. It's best to accept and move on, instead of… My parents were always hopeful that the brothers would be together, but it was not destined to happen."
Euronews
6 hours ago
- Health
- Euronews
EU regulator backs new Alzheimer's drug, months after rejecting it
The European Union's medicines regulator is reversing course on its decision to block a new Alzheimer's disease treatment, saying the drug can be offered to certain patients under strict safety protocols. In late March, the European Medicines Agency's (EMA) drug evaluators said the risks did not outweigh the benefits for the medicine donanemab, which can slow the progression of early-stage Alzheimer's but also raises the risk of potentially deadly brain swelling and bleeding. But in a revised opinion on Friday, the group said donanemab can be offered to a specific subset of Alzheimer's patients in tightly controlled settings. Donanemab, which is sold by Eli Lilly as Kisunla, is a monoclonal antibody taken via a once-monthly infusion. It's already been approved in the United Kingdom, the United States, Japan, and China. In a clinical trial, Kisunla slowed dementia symptoms by up to 35 per cent over 18 months – but three people died with serious amyloid‑related imaging abnormalities (ARIA), which are a common side effect of the medicine that can cause swelling and bleeding in the brain. Two of these patients carried a type of gene that raises the risk of Alzheimer's, and Lilly had suggested that the medicine only be offered to people who do not have the gene. In March, the EMA committee said that people without the gene were still at risk of fatal complications from ARIA. On Friday, the group said the drug can be offered to early Alzheimer's patients who have at most one copy of the gene – but only in a controlled access programme with medical teams that know how to detect and treat ARIA. Patients must also start at a lower dose. The EMA said that with those measures in place, its advisory group 'concluded that Kisunla's benefits outweigh its risks in noncarriers and people with just one copy' of the gene. The European Commission has the final say on whether a new drug or vaccine is approved, but it usually adopts the EMA evaluators' recommendations. That's why drugmaker Lilly had asked the EMA group to reconsider its negative opinion on Kisunla. It argued that ARIA is usually temporary and does not cause symptoms in most cases. Alzheimer's groups were also disappointed by the initial decision. At the time, Alzheimer Europe said that while patient safety is important, strict prescribing rules and safety monitoring could help ensure dementia patients have access to the new drug while keeping it away from those at higher risk of serious side effects. Notably, the EMA and the Commission recently greenlit another Alzheimer's drug, Leqembi, that comes with similar side effects for people with the gene. In that case, the EMA group had also first refused the drug, but later recommended that it be offered to people with only one or no copies of the gene – making it the first medicine of its kind authorised in the EU. The Commission is expected to make a final decision on Kisunla in the coming months.
